Serum galectin-3 levels in patients with Behçet's disease: Association with disease activity over a long-term follow-up

Journal of the European Academy of Dermatology and Venereology

Volumn 25, Issue 10, 2011, Pages 1168-1173

  Ozden M G ^a   Cayci Y T ^a   Tekin, H ^a   Coban A Y ^a   Aydin, F ^a   Senturk N ^a   Bek, Y ^a   Canturk T ^a   Turanli, A Y ^a  

^a ONDOKUZ MAYIS UNIVERSITY   (Turkey)

Author keywords

activity marker; Beh et's disease; Beh et's syndrome; galectin; galectin 3; vascular involvement

Indexed keywords

ANTICOAGULANT AGENT; AZATHIOPRINE; COLCHICINE; CYCLOSPORIN A; GALECTIN 3; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE;

ANTICOAGULANT THERAPY; ARTHRITIS; ARTICLE; BEHCET DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; ERYTHEMA NODOSUM; EYE DISEASE; FEMALE; FOLLOW UP; GENITAL ULCER; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LEUCOCYTOCLASTIC VASCULITIS; MAJOR CLINICAL STUDY; MALE; NECROTIZING ARTERITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RASH; SKIN BIOPSY; THROMBOPHLEBITIS; VASCULITIS;

ADOLESCENT; ADULT; BEHCET SYNDROME; BIOLOGICAL MARKERS; BIOPSY; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GALECTIN 3; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SKIN; VASCULITIS, LEUKOCYTOCLASTIC, CUTANEOUS; YOUNG ADULT;

EID: 80052994099     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2010.03941.x     Document Type: Article

References (40)

1. Türköz Y, Evereklioǧlu C, Mehmet N, et al. Plasma malondialdehyde levels in Behçet's disease with or without ocular involvement. Adv Reprod 2000; 4: 31-36.
2. Barondes SH, Castronovo V, Cooper DNW, et al. Galectins: a familly of animal galactoside-binding lectins. Cell 1994; 76: 597-598.
3. Lee YJ, Kang SW, Song JK, et al. Serum galectin-3 and galectin-3 binding protein levels in Behçet's disease and their association with disease activity. Clin Exp Rheumatol 2007; 25: 41-45.
4. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990; 335: 1078-1080.
5. Bhakta BB, Prennan P, James TE, et al. Behçet's disease: evaluation of a new instrument to measure clinical activity. Rheumatology 1999; 38: 728-733.
6. Hamuryudan V, Fresko I, Direskeneli H, et al. Evaluation of the Turkish translation of a disease activity form for Behçet's syndrome. Rheumatology 1999; 38: 734-736.
7. Baskan EB, Yilmaz E, Saricaoglu H, et al. Detection of parvovirus B19 DNA in the lesional skin of patients with Behçet's disease. Clin Exp Dermatol 2007; 32: 186-190.
8. Meguro A, Inoko H, Ota M, et al. Genetics of Behçet's disease inside and outside the MHC. Ann Rheum Dis 2010; 69: 747-754.
9. Pay S, Simşek I, Erdem H, Dinç A,. Immunopathogenesis of Behçet's disease with special emphasize on the possible role of antigen presenting cells. Rheumatol Int 2007; 27: 417-424.
10. Ozdemir R, Barutcu I, Sezgin AT, et al. Vascular endothelial function and plasma homocysteine levels in Behcet's disease. Am J Cardiol 2004; 94: 522-525.
11. Frassanito MA, Dammacco R, Cafforio P, Dammacco F,. Th1 polarization of the immune response in Behçet's disease. Arthritis Rheum 1999; 42: 1967-1974.
12. Coskun B, Saral Y, Gödekmerdan A, et al. Activation markers in Behçet's disease. Skinmed 2005; 4: 282-286.
13. Bhakta BB, Brennan P, James TE, et al. Behçet's disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford) 1999; 38: 728-733.
14. Erkilic K, Evereklioglu C, Çekmen M, et al. Adenosine deaminase enzyme activity is increased and negatively correlates with catalase, superoxide dismutase and glutathione peroxidase in patients with Behcet's disease: original contributions/clinical and laboratory investigations. Mediators Inflamm 2003; 12: 107-116.
15. Mege JL, Dilsen N, Sanguedolce V, et al. Overproduction of monocyte derived tumor necrosis factor α, interleukin (IL)- 6, IL-8 and increased neutrophil superoxide generation in Behçet's disease: a comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993; 20: 1544-1549.
16. Sahin S, Akoǧlu T, Direskeneli H, et al. Neutrophil adhesion to endothelial cells and factors affecting adhesion in patients with Behçet's disease. Ann Rheum Dis 1996; 55: 128-133.
17. Sahin S, Lawrence R, Direskeneli H, et al. Monocyte activity in Behçet's disease. Br J Rheumatol 1996; 35: 424-429.
18. Takeno M, Kariyone A, Yamashita N, et al. Excessive function of peripheral blood neutrophils from patients with Behçet's disease and from HLA-B51 transgenic mice. Arthritis Rheum 1995; 38: 426-433.
19. Yamashita N,. Hyperreactivity of neutrophils and abnormal T cell homeostasis: a new insight for pathogenesis of Behçet's disease. Int Rev Immunol 1997; 14: 11-19.
20. Carletto A, Pacor ML, Biasi D, et al. Changes of neutrophil migration without modification of in vitro metabolism and adhesion in Behcet's disease. J Rheumatol 1997; 24: 1332-1336.
21. Chi W, Zhu X, Yang P, et al. Upregulated IL-23 and IL-17 in Behçet patients with active uveitis. J Invest Ophthalmol Vis Sci 2008; 49: 3058-3064.
22. Ekinci NS, Alpsoy E, Karakas AA, et al. IL-17Aasanimportant role in the acute attacks of Behçet's disease. J Invest Dermatol 2010; 130: 2136-2138.
23. Rossiter H, Alon R, Kupper TS,. Selectins, T-cell Rolling and inflammation. Mol Med Today 1997; 3: 214-222.
24. Cooper DN, Barondes SH,. God must love galectins; he made so many of them. Glycobiology 1999; 9: 979-984.
25. Rabinovich GA,. Galectins: an evolutionarily conserved family of animal lectins with multifunctional properties; a trip from the gene to clinical therapy. Cell Death Differ 1999; 6: 711-721.
26. Liu FT,. Galectins: a new family of regulators of inflammation. Clin Immunol 2000; 97: 79-88.
27. Hughes RC,. Secretion of the galectin family of mammalian carbohydrate binding proteins. Biochim Biophys Acta 1999; 1473: 172-185.
28. Rabinovich GA, Daly G, Dreja H, et al. Recombinant galectin-1 and its genetic delivery suppresscollagen-induced arthritis via T-cell apoptosis. J Exp Med 1999; 190: 385-398.
29. Levi G, Tarrab-Hazdai R, Teichberg VI,. Prevention and therapy with electrolectin of experimental autoimmune myasthenia gravis in rabbits. Eur J Immunol 1983; 13: 500-507.
30. Santucci L, Fiorucci S, Cammilleri F, et al. Galectin-1 exerts immunomodulatory and protective effects on concanavalin-A-induced hepatitis in mice. Hepatology 2000; 31: 399-406.
31. Cortegano I, del Pozo V, Cárdaba B, et al. Galectin-3 down-regulates IL-5 gene expression on different celltypes. J Immunol 1998; 161: 385-389.
32. Joo HG, Goedegebuure PS, Sadanaga N, et al. Expression and function of galectin-3, a beta-galactoside-binding protein in activated T lymphocytes. J Leukoc Biol 2001; 69: 555-564.
33. Karlsson A, Follin P, Leffler P, Dahlgren C,. Galectin-3 activates the NADPH oxidase in exudated but not peripheralblood neutrophils. Blood 1998; 91: 3430-3438.
34. Yamaoka A, Kuwabara I, Frigeri LG, Liu FT,. Human lectin, galectin-3(epsilon bp/Mac-2), stimulates superoxide production by neutrophils. J Immunol 1995; 154: 3479-3487.
35. Jeng KC, Frigeri LG, Liu FT,. An endogenous lectin, galectin-3 (epsion BP/Mac-2), potentiates IL-1production by human monocytes. Immunol Lett 1994; 42: 113-116.
36. Sano H, Hsu DK, Yu L, et al. Human galectin-3 is a novel chemoattractant for monocytes and macrophages. J Immunol 2000; 165: 2156-2164.
37. Sato S, Ouellet N, Pelletier I, et al. Role of galectin-3 as an adhesion molecule for neutrophil extravasation during streptococcal pneumonia. J Immunol 2002; 168: 1813-1822.
38. Hsu DK, Yang RY, Pan Z, et al. Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Am J Pathol 2000; 156: 1073-1083.
39. Colnot C, Ripoche MA, Milon G, et al. Maintenance of granulocyte numbers during acute peritonitis is defective in galectin-3-null mutant mice. Immunology 1998; 94: 290-296.
40. Rabinovich GA, Baum LG, Tinari N, et al. Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response? Trends Immunol 2002; 23: 313-320.